Abstract
Thrombomodulin (TM) is an endothelial glycoprotein that is present in all blood vessels. Five percent of all patients with atypical hemolytic uremic syndrome (aHUS) have mutations in the gene coding for TM, with a peak presentation in young children. Mutations often translate into quantitative and qualitative abnormalities of this endothelial glycoprotein. Outcome of the TM-associated aHUS is relatively poor with frequent relapses after transplantation despite its membrane-bound character. We observed a woman presenting with malignant hypertension (MHT) and associated kidney, brain, cardiac, and hematological involvement with thrombotic microangiopathy on kidney biopsy. She had a documented mutation of the gene coding for TM, which was associated with both aHUS and an increased risk for venous and arterial thrombosis. As TM has anti-coagulant, anti-inflammatory, and cytoprotective properties and also attenuates alternative complement activation, this glycoprotein could play an active role in other diseases with endothelial involvement apart from aHUS. We discuss the potential role of TM in the pathophysiology of various endotheliopathies including MHT. We also provide a framework for future therapeutic options.
References
1.
Cremer A, Amraoui F, Lip GY, Morales E, Rubin S, Segura J, Van den Born BJ, Gosse P: From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens 2016; 30: 463–466.
2.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, et al: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension 2017; 71: 1269–1324.
3.
Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, Damoiseaux JGMC, Reutelingsperger CP, van Paassen P; Limburg Renal Registry: Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017; 91: 420–425.
4.
Shavit L, Reinus C, Sotki I: Severe renal failure and microangiopathic hemolysis induced by malignant hypertension-case series and review of literature. Clin Nephrol 2010; 73: 147–152.
5.
Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C: Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014; 40: 444–464.
6.
Wenzel UO, Bode M, Köhl J, Ehmke H: A pathogenic role of complement in arterial hypertension and hypertensive organ damage. Am J Physiol Heart Circ Physiol 2017; 312:H349–H354.
7.
Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM: Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345–357.
8.
Martin FA, Murphy RP, Cummins PM: Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol 2013; 304:H1585–1597.
9.
Leung LL, Myles T, Nishimura T, Song JJ, Robinson WH: Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008; 45: 4080–4083.
10.
Li YH, Kuo CH, Shi GY, Wu HL: The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci 2012; 27: 19–34.
11.
Dusse LM, Carvalho MG, Getliffe K, Voegeli D, Cooper AJ, Lwaleed BA: Increased circulating thrombomodulin levels in pre-eclampsia. Clin Chim Acta 2008; 387: 168–171.
12.
Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi K Shirakawa S, Hayashi T, Suzuki K: Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Hematol 1993; 44: 85–88.
13.
Mori Y, Wada H, Okugawa Y, Tamaki S, Nakasaki T, Watanabe R, Gabazza EC, Nishikawa M, Minami N, Shiku H: Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost 2001; 7: 5–9.
14.
Stratton RJ, Pompon L, Coghlan JG, Pearson JD, Black CM: Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis 2000; 59: 132–134.
15.
Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R: Circulating thrombomodulin levels are related to latent progression of atherosclerosis in hypertensive patients. Hypertens Res 2003; 26: 479–483.
16.
Papadopoulos DP, Thomopoulos C, Mourouzis I, Kotrotsou A, Sanidas E, Papazachou U, Daskalaki M, Makris TK: Masked -hypertension unfavourably affects haemostasis parameters. Blood Press 2011; 20: 218–221.
17.
Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK: Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the atherosclerosis risk in communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 1729–1734.
18.
Thorand B, Baumert J, Herder C, Meisinger C, Koenig W: Soluble thrombomodulin as a predictor of type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984–1998. Diabetologia 2007; 50: 545–548.
19.
McLaren M, Elhadd TA, Greene SA, Belch JJ: Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Appl Thromb Hemost 1999; 5: 21–24.
20.
Olivot JM, Labreuche J, Aiach M, Amarenco P; GENIC Investigators: Soluble thrombomodulin and brain infarction: case-control and prospective study. Stroke 2004; 35: 1946–1951.
21.
Béland S, Vallin P, Désy O, Lévesque E, De Serres SA: Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin. J Thromb Haemost 2017; 15: 1020–1031.
22.
Tanaka K, Salunya T, Motomiya Y, Motomiya Y, Oyama Y, Yamakuchi M, Maruyama I: Decreased expression of thrombomodulin in endothelial cells by fibroblast growth factor-23/α-Klotho. Ther Apher Dial 2017; 21: 395–404.
23.
Fernandez GC, Te Loo MW, van der Velden TJ, van der Heuvel LP, Palermo MS, Monnens LL: Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome. Pediatr Nephrol 2003; 18: 1066–1068.
24.
Turner RJ, Bloemenkamp KW, Bruijn JA, Baelde HJ: Loss of thrombomodulin in placental dysfunction in preeclampsia. Arterioscler Thromb Vasc Biol 2016; 36: 728–735.
25.
Sartain SE, Turner NA, Moake JL: TNF regulates essential alternative complement pathway components and impairs activation of protein C in human glomerular endothelial cells. J Immunol 2016; 196: 832–845.
26.
Kunz G, Ohlin AK, Adami A, Zöller B, Svensson P, Lane DA: Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function. Blood 2002; 99: 3646–3653.
27.
Ohlin AK, Norlund L, Marlar RA: Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997; 78: 396–400.
28.
Franchi F, Biguzzi E, Cetin I, Facchetti F, Radaelli T, Bozzo M, Pardi G, Faioni EM: Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br J Haematol 2001; 114: 641–646.
29.
Xu K, Jin J, Tan S: Association of thrombomodulin gene polymorphisms with susceptibility to atherosclerotic diseases: a meta-analysis. Ann Hum Genet 2016; 80: 172–181.
30.
Uchiba M, Okajima K, Murakami K, Nawa K, Okabe H, Takatsuki K: Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 1995; 74: 1265–1270.
31.
Sharfuddin AA, Sandoval RM, Berg DT, McDougal GE, Campos SB, Phillips CL, Jones BE, Gupta A, Grinnell BW, Molitoris BA: Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 2009; 20: 524–534.
32.
Kadono K, Uchida Y, Hirao H, Miyauchi T, Watanabe T, Iida T, Ueda S, Kanazawa A, Mori A, Okajima H, Tarajima H, Uemoto S: Thrombomodulin attenuates inflammatory damage due to liver ischemia and reperfusion injury in mice in toll-like receptor 4-dependent manner. Am J Transplant 2017; 17: 69–80.
33.
Shin M, Hino H, Tamura M, Ishizuka B, Tanaka M, Suzuki N, Tateda T: Thrombomodulin improves maternal and fetal conditions in an experimental pre-eclampsia rat model. J Obstet Gynaecol Res 2014; 40: 1226–1234.
34.
Suyama K, Kawasaki Y, Miyazaki K, Kanno S, Ono A, Ohara S, Sato M, Hosoya M: The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice. Nephrol Dial Transplant 2015; 30: 969–977.
35.
Su EJ, Geyer M, Wahl M, Mann K, Ginsburg D, Brohmann H, Petersen KU, Lawrence DA: The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost 2011; 9: 1174–1182.
36.
Pathak R, Ghosh SP, Zhou D, Hauer-Jensen M: The vitamin E analog gamma-tocotrienol (GT3) and statins synergistically up-regulate endothelial thrombomodulin (TM). Int J Mol Sci 2016; 17:pii:E1937.
37.
D’arrigo G, Pizzini P, Cutrupi S, Tripepi R, Tripepi G, Mallamaci F, Zoccali C: Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial. Nephrol Dial Transplant 2018, Epub ahead of prin.
38.
Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T: Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 2015; 13: 508–519.
39.
Kawasaki Y, Suyama K, Ono A, Oikawa T, Ohara S, Suzuki Y, Sakai N, Hosoya M: Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome. Pediatr Int 2013; 55:e139–142.
40.
Honda T, Ogata S, Mineo E, Nagamori Y, Nakamura S, Bando Y, Ishii M: A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin α. Pediatrics 2013; 131:e928–e933.
41.
Waters AM, Licht C: aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 2011; 26: 41–57.
42.
Fakhouri F, Zuber Z, Fremeauch-Bacchi, Loirat C: Haemolytic uraemic syndrome. Lancet 2017; 390: 681–696.
43.
Peyvandi F, Rossio R, Ferrari B, Lotta LA, Pontiggia S, Ghiringhelli Borsa N, Pizzuti M, Donadelli R, Piras R, Cugno M, Noris M: Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes. J Thromb Haemost 2016; 14: 340–345.
44.
Noris M, Caprioli R, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844–1859.
45.
Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L: Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant 2013; 17:E177–E181.
46.
Chinchilla S, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, Pena A, Lopez Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S: Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic syndrome. Clin J Am Soc Nephrol 2014; 9: 1516–1518.
47.
Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GY: Persistent macrovascular and microvascular dysfunction in patients with malignant hypertension. Hypertension 2011; 57: 490–496.
48.
Ohlin AK, Marlar RA: Thrombomodulin gene defects in families with thromboembolic disease – a report on four families. Thromb Haemost 1999; 81: 338–344.
49.
Ishibazawa A, Nagaoka T, Takahashi T, Yamamoto K, Kamiya A, Ando J, Yoshida A: Effects of shear stress on the gene expressions of endothelial nitric oxide synthase, endothelin-1, and thrombomodulin in human retinal microvascular endothelial cells. Invest Opthalmol Vis Sci 2011; 52: 8496–8504.
50.
Mathew RO, Nayer A, Asif A: The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J Am Soc Hypertens 2016; 10: 352–359.
51.
Dufourcq P, Seigneur M, Pruvost A, Dumain P, Belloc F, Amiral J, Boisseau MR: Membrane thrombomodulin levels are decreased during hypoxia and restored by cAMP and IBMX. Thromb Res 1995; 77: 305–310.
52.
Prasad K, Mishra M: Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension? Int J Angiol 2017; 26: 1–11.
53.
Ito T, Kakihana Y, Maruyama I: Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic disease. Expert Opin Ther Targets 2016; 20: 151–158.
54.
Lusco M, Fogo A, Najafian B, Alpers C: AJKD atlas of renal pathology: thrombotic microangiopathy. Am J Kidney Dis 2016; 68: 33–34.
55.
Larsen CP, Wilson JD, Best-Rocha A, Beggs ML, Hennigar RA: Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy. Mod Pathol 2018; 31: 488–494.
56.
Taylor CM, Machin S, Wigmore SJ, Goodship THJ: Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010; 148: 37–47.
57.
Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676–1687.
58.
Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V: An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31: 15–39.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
